Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809)
The Prostate · 2026
DOI: 10.1002/pros.70125 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Prostate, 2026. Verfasst von Anna C Ferrari und 12 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore-Einstein Comprehensive Cancer Center, Bronx, New York, USA. Hauptthemen laut MEDLINE: Anilides, Tosyl Compounds, Nitriles, Prostate-Specific Antigen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Combined inhibition of AKT and the androgen receptor (AR) might be more efficacious than AR inhibition alone in biochemical recurrence (BCR) of prostate cancer (PC) by additive effects on the two effector pathways. Patients and Methods E2809 assigned 108 high‐risk BCR patients (1:1, arm‐A: arm‐B) to two phases with 4‐week cycles: first (PreBic) phase (3 cycles), arm‐B received AKT inhibitor MK‐2206 200 mg 2x/week, arm‐A was observation; second phase, bicalutamide (Bic), 50 mg daily, was added to each arm. The PreBic phase assessed whether AKT inhibition changed PSA, reflecting AR activation. Exploratory primary endpoint (EP1) at 6–8 Bic cycles and secondary EP2 at cycle 14 compared the proportion of cases with ≥stable disease (SD) or progressive disease (PD).
Results
PreBic phase: 70% arm‐B vs 32% arm‐A patients had a ≥ 60% PSA rise ( p = 0.02). MK‐2206 skin toxicity (38% grade ≥ 3) drove high withdrawal prior to EP1. Bic phase: at EP1, inter‐arm PSA response (81%/82%) or PD (19%/18%) was equal. At EP2, PD was greater in arm‐A than arm B (36% vs 11%; p = 0.04). In subgroups defined by PreBic phase PD (PBPD; PSA rise ≥ 25%), 9/16 arm‐A vs 0/7 arm‐B cases experienced PD at EP2 ( p = 0.02); overall between PBPD‐subgroups, 73% arm‐A vs 27% arm‐B experienced PD.
Conclusions
The results suggest that latent improved outcome of high‐risk BCR patients (mean PSA doubling time 4.4 months) on combined MK‐2206+Bic versus Bic alone was attributable to a subgroup identified by crosstalk AR activation secondary to inhibition of AKT. Toxicity may affect tolerance of sustained AKT‐AR inhibition. Clinical Trial Registration ClinicalTrials. gov number, NCT01251861.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Montefiore-Einstein Comprehensive Cancer Center, Bronx, New York, USA.
- Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts, USA.
- University of Texas Health Science Center, San Antonio, Texas, USA.
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
- Johns Hopkins University, Baltimore, Maryland, USA.
- M D Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Anna C Ferrari
Förderung
- NCI NIH HHS
Zitieren
APA
Ferrari, A. C., Chen, Y. H., Rodríguez, R., Hudes, G. R., Antonarakis, E. S., Hahn, N. M., Ma, H., Plimack, E. R., Mayer, T., Carthon, B. C., Liu, G., Carducci, M. A., & DiPaola, R. (2026). Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809). The Prostate. https://doi.org/10.1002/pros.70125
Vancouver
Ferrari AC, Chen YH, Rodríguez R, Hudes GR, Antonarakis ES, Hahn NM, et al. Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809). The Prostate. 2026. doi:10.1002/pros.70125
BibTeX
@article{Ferrari2026,
author = {Ferrari, Anna C and Chen, Yu-Hui and Rodríguez, Ronald and Hudes, Gary R and Antonarakis, Emmanuel S and Hahn, Noah M and Ma, Hilary and Plimack, Elizabeth R and Mayer, Tina and Carthon, Bradley C and Liu, Glenn and Carducci, Michael A and DiPaola, Robert},
title = {Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809)},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70125}
}
EUVIMED